MeiraGTx to Participate in Upcoming Investor Conferences
April 24, 2024 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes,...
Leber Congenital Amaurosis Pipeline Insight 2024, Featuring Key Players ProQR Therapeutics, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies, IVERIC bio and MeiraGTx
April 22, 2024 07:51 ET
|
Research and Markets
Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "Leber congenital amaurosis - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.The report provides...
AAV Vectors in Gene Therapy Pipeline Landscape Report 2024: Comprehensive Insights about 70+ Companies and 235+ Pipeline Drugs
April 19, 2024 07:31 ET
|
Research and Markets
Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "AAV vectors in gene therapy - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "AAV vectors in gene...
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
April 18, 2024 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave...
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
March 14, 2024 08:30 ET
|
MeiraGTx
- Company aligned with FDA on requirements for ongoing Phase 2 AQUAx2 clinical trial for Grade 2/3 radiation-induced xerostomia to be considered pivotal supporting potential BLA filing ...
Gene Therapies In Ophthalmology Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
February 19, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Gene Therapies In Ophthalmology Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment |...
Burns Market is Projected to Grow During the Study Period (2019–2032), Predicts DelveInsight | Key Players in the Market - Aegle Therapeutics, Skingenix, Inc., Stratatech, MediWound Ltd
February 15, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Burns Market is Projected to Grow During the Study Period (2019–2032), Predicts DelveInsight | Key Players in the Market - Aegle Therapeutics,...
Gene and Cell Therapies Targeting CNS Disorders Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight
February 14, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Gene and Cell Therapies Targeting CNS Disorders Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight The gene and cell...
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
February 13, 2024 08:00 ET
|
MeiraGTx
LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the achievement...
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
December 21, 2023 07:00 ET
|
MeiraGTx
- MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) for a total of up to...